features: Diffuse Large B-Cell Lymphoma

VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas

VJHemOnc is pleased to bring you a feature exploring the latest developments in the treatment of NHL, with leading experts…

VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…

Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…

The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…

VJHemOnc is excited to bring you highlights from the 47th Annual Meeting of the European Group for Blood and Marrow…

Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…

VJHemOnc are excited to present late-breaking abstracts and key trial updates announced at this year’s virtual EHA meeting!

A study presented during the 2020 American Society of Clinical Oncology and Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium,…

Twenty-five years ago, almost to the day, there was a paradigm shift in the classification of lymphoma.